

Principles of AE management

Dr Niara Oliveira

Mater Hospital, Brisbane, Australia

EV as first-line therapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. Combination therapy with pembrolizumab.

EV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 or programmed death-ligand 1 inhibitor, and have received a platinum-containing chemotherapy

1L, first line; EV, enfortumab vedotin;
LA/mUC, locally advanced/metastatic urothelial carcinoma; P, pembrolizumab;
PD-1/L1, programmed cell death-1/ligand 1.
PADCEV® (enfortumab vedotin). Prescribing Information
July 2025 | MAT-KR-PAD-2025-00076

Adverse events should be reported.

For Korea, healthcare professionals are asked to report any suspected adverse reactions to Astellas Pharma Korea, Inc

(Telephone: +82 10 5254 3389; Email: safety-kr@kr.astellas.com)

Prescribing information is available at the end of this presentation. This promotional meeting is fully sponsored and supported by Astellas, including speaker-related honoraria and production of materials. It is intended for healthcare professionals only.

 **PADCEV**
enfortumab vedotin
Injection for IV infusion 20 mg & 30 mg vials **astellas**

Disclosures

- Consultancy, Advisory Role, Educational Sponsorship, Writing Engagement and Speaker for (in alphabetical order):
 - Astellas, AstraZeneca, Bayer, BMS, Daiichii Sankyo, Eisai, Ipsen, J&J, Merck Serono, MSD, Pfizer, The Limbic
- No shares or personal research funding to declare
- ESMO DOI #00021152

Take-home messages



Close monitoring for AEs during treatment with EV is important¹



Early identification and effective care can help ensure patients are able to continue to receive their treatment, to ensure patients receive optimal treatment outcomes¹



Patients continue to benefit from EV monotherapy even when dose modifications are required to manage AEs²

Please refer to the Korean PI for
PADCEV® (enfortumab vedotin) via
the following QR Code:

<PADCEV 20mg>



<PADCEV 30mg>

